BioMarin’s Initial 6-Month Data From Phase 2 Study of Vosoritide (BMN 111) in Children With Achondroplasia Presented at the American Society for Bone and Mineral Research Annual 2015 Meeting

SAN RAFAEL, Calif., Oct. 12, 2015 (GLOBE NEWSWIRE) — BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dr. Melita Irving, Clinical Geneticist, Guy’s and St Thomas’ NHS Foundation Trust, Evelina Children’s Hospital London, UK, presented the...